Data, Risk, and Digitalization: Navigating the FDA’s Unified Quality Paradigm

The landscape of pharmaceutical manufacturing is undergoing a profound paradigm shift, moving away from reactive compliance and toward predictive, science-based quality ecosystems. For GMP executives, staying ahead of this evolution requires more than just tracking regulatory changes; it demands a deep understanding of how global harmonization shapes shop-floor reality. The FDA’s recently updated guidance, “Q8, … Read more